You are here

ASSAY OF NUCLEOSIDES IN SMALL-CELL CARCINOMA OF THE LUNG

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 7141
Amount: $50,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1987
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
Po Box 7539
Columbia, MO 65205
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 JOHN E MCENTIRE PHD
 (314) 874-2481
Business Contact
Phone: () -
Research Institution
N/A
Abstract

SEVERAL INVESTIGATORS HAVE IMPLICATED MODIFIED RIBONUCLEOSIDES, PRESUMABLY MODIFICATION PRODUCTS FROM TRANSFER RIBONUCLEIC ACIDS (TRNAS), AS POTENTIAL BIOLOGICAL MARKERS FOR CANCER. ELEVATED LEVELS OF THESE MOLECULES HAVE BEEN QUANTITATED IN THE SERUM OR URINE OF CANCER PATIENTS BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY-ULTRAVIOLET (HPLC-UV) OR IMMUNOASSAY. IN THIS PROPOSAL, IMBIC CORPORATION WILL DEMONSTRATE THE FEASIBILITY OF PREPARING ANTIBODIES TO TWO COMMON MODIFIED NUCLEOSIDES AND THE DEVELOPMENT OF AN IMMUNOASSAY FOR THEIR EASY QUANTITATION. ADDITIONALLY, THE LEVELS OF 30 MODIFIED NUCLEOSIDES WILL BE DETERMINED IN THE SERUM FROM LUNG CANCER PATIENTS AND NORMAL CONTROLS. THESE DATA WILL BE SUBJECTED TO PATTERN RECOGNITION ANALYSIS TO DEVELOP A PROFILE OF SELECTED SERUM-MODIFIED NUCLEOSIDE CONCENTRATIONS THAT CAN DEFINE BIOLOGICAL MARKERS FOR LUNG CANCER. AN IMMUNOASSAY DIAGNOSTIC KIT WILL BE DEVELOPED TO DETECT THESE BIOMARKERS WITH HIGH SENSITIVITY AND SPECIFICITY.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government